ENTITY: Sanofi SA | Pharma Transformation via AI-Accelerated Drug Discovery and Vaccine Platform Growth

A Macro Intelligence Memo | June 2030 | Investor Edition

FROM: The 2030 Report | Healthcare and Pharmaceutical Analysis Division DATE: June 28, 2030 RE: Sanofi Strategic Repositioning; AI-Accelerated Drug Discovery Pipeline; Vaccine Portfolio Expansion; Valuation Framework and Investment Thesis

SUMMARY: THE BEAR CASE vs. THE BULL CASE

BEAR CASE: - Current Stock Price: €55/share (June 2030) - Bear Thesis: AI drug discovery pipeline disappoints; clinical trial failures increase; vaccine market saturation from competitors; specialty care pricing pressure; biosimilar competition accelerates; geopolitical supply chain disruption; operating margins compress to 22-23%; organic growth stalls at 1-2%; dividend sustainability questioned - Bear Target (2035): €48-56/share (flat to -14% downside including dividends) - Downside Scenario Returns: -14% to +5% over 5 years (with 2.5% dividends); market underperformance - Positioning: Hold existing positions; reduce on strength above €60; avoid new positions; monitor R&D productivity and pipeline progression

BULL CASE: - Management Actions: AI drug discovery launches 3-4 new clinical programs; specialty care pipeline succeeds (launches 2-3 new drugs); vaccine revenue accelerates to €13-15B; operating margins expand to 26-27%; maintains dividend at 2.5-3.0% yield; initiates €3-4B buyback program; pursues strategic M&A of specialty care/vaccine assets - Stock Trajectory: €55 → €72 (2032) → €95-115 (2035); operating margins reach 26-27%; organic revenue growth 4-5%; dividend grows to €1.50-1.75/share - Entry Points: Accumulate on weakness below €52/share; add on recession weakness to €45-48; maintain core position; increase on vaccine/specialty care pipeline announcements - Bull Case Return: +73-109% by 2035 (11.5-13.5% CAGR including 2.7-3%+ dividends); multiple expansion if specialty care growth accelerates

EXECUTIVE SUMMARY

Sanofi SA (EURONEXT: SAN), Europe's largest pharmaceutical company by market capitalization, successfully navigated transformation (2025-2030) by executing disciplined strategic repositioning toward three sustainable growth pillars: specialty care (40% of revenue, +5% growth trajectory), vaccines (20% of revenue, +7% growth), and AI-accelerated drug discovery (capability enablement for pipeline acceleration).

The company's stock price appreciated from EUR 40/share (June 2025) to EUR 55/share (June 2030), representing 37.5% total return including dividends. Stock performance reflected market recognition of successful strategic execution and sustainable business model transition. While performing modestly better than broader European pharma indices, Sanofi's returns reflected realistic expectations about moderate growth in mature pharmaceutical markets.

By June 2030, Sanofi is positioned as a mid-to-large pharmaceutical company offering combination of defensive characteristics (stable vaccines and specialty care revenues), modest organic growth drivers (AI drug discovery pipeline acceleration), and reasonable valuation (18.5x forward P/E), making it suitable for dividend-focused and balanced portfolio allocators.

Key Metrics (June 2030): - Stock price: EUR 55/share - Market capitalization: EUR 140B - Forward P/E: 18.5x - EV/EBITDA: 8.2x - Dividend yield: 2.7% - Revenue (annualized): EUR 55.8B - Operating margin: 24.5%

SECTION ONE: STRATEGIC TRANSFORMATION AND BUSINESS ARCHITECTURE

Portfolio Transition from Generics to Specialty Care

Sanofi's fundamental strategic shift reflects retreat from unprofitable commodity generics business toward higher-margin specialty care:

Business Mix Evolution (2025 → 2030):

Generics Segment: - 2025: EUR 14.2B revenue (32% of total), declining 3-4% annually - 2030: EUR 12.0B revenue (21% of total), continuing -2-3% annual decline - Rationale: Commoditized pricing, limited growth, subject to generic competition - Strategic response: Selective rationalization; focus on niche generics with defensibility

Specialty Care Segment: - 2025: EUR 20.1B revenue (45% of total), growing +4-5% annually - 2030: EUR 22.4B revenue (40% of total), growing +5-6% annually - Growth drivers: Dupilumab (atopic dermatitis, asthma, COPD expansion), oncology, rare diseases - Margins: 55-65% gross margins (vs. 30-40% in generics) - Strategy: Selective portfolio additions, premium pricing for specialty indications

Vaccines Segment: - 2025: EUR 9.1B revenue (20% of total), growing +6-8% annually - 2030: EUR 11.2B revenue (20% of total), growing +7-9% annually - Growth drivers: RSV vaccine (EUR 4.8B by 2030), influenza, meningococcal vaccines - Margins: 65-72% gross margins (very high-margin business) - Strategy: Aggressive vaccine portfolio expansion, emerging market penetration

Other Segments: - Contract manufacturing and other: EUR 10.2B (remaining 18%)

Strategic Logic: Shift from volume-driven, low-margin generics to specialty-driven, high-margin portfolio generates operating leverage. Mix shift alone drives 200-250 bps margin expansion even absent organic improvement.

RSV Vaccine Blockbuster Franchise

The RSV (Respiratory Syncytial Virus) vaccine represents Sanofi's most successful recent development and primary growth engine:

RSV Vaccine Development and Launch: - Phase III trial (2023-2024): Demonstrated strong efficacy in older adults - Regulatory approval (2028): FDA approval in US, EMA approval in Europe - Commercial launch (2028): Strong uptake in developed markets

Financial Performance (Actual through 2030): - 2028: EUR 1.5B revenue (launch year) - 2029: EUR 3.2B revenue (+113% YoY, strong adoption) - 2030: EUR 4.8B revenue (+50% YoY, market maturation beginning)

Market Dynamics: - Target market: Age 60+ adults (high-risk for RSV); immunocompromised; younger adults with chronic disease - Total addressable market: ~400M patients globally - Peak sales potential: EUR 8-10B globally (achieved by 2034-2035) - Pricing: EUR 300-400 per dose; single dose provides seasonal protection - Competition: Pfizer vaccine in development; Moderna exploring RSV candidates; GSK has RSV approval planned

Strategic Significance: RSV vaccine provides sustainable, high-margin revenue stream and demonstrates Sanofi's vaccine development capability. Success is replicable across other vaccine indications.

AI-Accelerated Drug Discovery

Sanofi has been relatively late in deploying AI for drug discovery compared to competitors (Roche, Merck), but acceleration 2026-2030 is evident:

AI Integration Timeline: - 2025: Limited AI deployment; single partnership with Google DeepMind - 2026-2027: Expanded partnerships; internal AI capability building - 2028-2030: Material AI integration; 40-50% of new Phase I programs utilize AI-optimized target selection

Impact on Pipeline: - 2025 baseline: 4-5 Phase I-II programs annually entering pipeline - 2030: 8-10 Phase I-II programs annually, with 40-50% utilizing AI optimization - Expected benefit: Improved probability of success (estimated +2-4 percentage points); faster time-to-clinic - Pipeline value: AI-accelerated programs valued 20-30% higher due to success probability improvement

Partnerships: - Google DeepMind: Target identification and validation - Internal: Expanded computational biology team (PhDs increased from 45 in 2025 to 120 in 2030) - External biotech: Lead optimization and early development partnerships

Expected Pipeline Impact: By 2035, AI-accelerated programs represent 25-30% of new approvals, incrementally increasing new product approvals from 1-2 annually to 2-3 annually.

SECTION TWO: FINANCIAL PERFORMANCE AND MARGINS

Revenue Growth and Mix Evolution

Sanofi's revenue growth (4.6% CAGR 2025-2030) reflects mix shift toward higher-growth specialty care and vaccines, offsetting declining generics:

Revenue by Segment (EUR Billions): | Year | Specialty | Vaccines | Generics | Other | Total | |------|-----------|----------|----------|-------|-------| | 2025 | 20.1 | 9.1 | 14.2 | 0.8 | 44.2 | | 2026 | 20.8 | 9.5 | 13.9 | 0.8 | 45.0 | | 2027 | 21.5 | 10.1 | 13.6 | 0.8 | 46.0 | | 2028 | 21.2 | 11.4 | 13.3 | 0.9 | 46.8 | | 2029 | 21.8 | 11.8 | 13.0 | 0.9 | 47.5 | | 2030 | 22.4 | 12.3 | 12.0 | 1.1 | 47.8 |

Growth Drivers: - Specialty care: +4.8% CAGR (Dupilumab expansion, oncology growth) - Vaccines: +6.2% CAGR (RSV ramp, meningococcal expansion) - Generics: -3.4% CAGR (structural decline, selective portfolio rationalization)

Note: 2030 revenue of EUR 47.8B reflects slight revision down from EUR 55.8B in earlier sources; latter appears to include OTC/other businesses.

Operating Margin Expansion

Sanofi has achieved meaningful operating margin expansion through mix shift:

Operating Margin Evolution: - 2025: 20.2% - 2026: 21.4% - 2027: 22.6% - 2028: 23.8% - 2029: 24.1% - 2030: 24.5%

Margin Drivers: - Mix shift to specialty (55-65% gross margins) and vaccines (65-72% gross margins) from generics (30-40% margins): +200-250 bps benefit - SG&A leverage as revenue grows modestly: +50-75 bps benefit - Offsetting: R&D investments (AI capability building, pipeline acceleration): -50 bps headwind

Expected Margin Evolution (2031-2035): - Target range: 25-27% - Drivers: Continued mix evolution, vaccine portfolio expansion, AI pipeline acceleration - Risk: Patent cliffs on key specialty drugs require new product introductions

Free Cash Flow and Capital Allocation

Sanofi generates substantial free cash flow, enabling dividend support and selective M&A:

Cash Flow Metrics (EUR Billions): | Year | Operating CF | CapEx | FCF | |------|--------------|-------|-----| | 2025 | 7.1 | 1.9 | 5.2 | | 2026 | 7.4 | 1.8 | 5.6 | | 2027 | 7.8 | 1.9 | 5.9 | | 2028 | 8.2 | 2.0 | 6.2 | | 2029 | 8.5 | 2.1 | 6.4 | | 2030 | 9.1 | 2.3 | 6.8 |

Capital Allocation (2025-2030): - Dividend payments: EUR 10.8B (60-70% of FCF) - Share buybacks: EUR 2.5B (modest program) - M&A: EUR 3.2B (selective acquisitions in vaccines, specialty care) - Debt reduction: Modest (maintaining investment-grade rating)

SECTION THREE: VALUATION FRAMEWORK AND SCENARIOS

Current Valuation (June 2030)

Sanofi at EUR 55/share trades at reasonable valuation for pharmaceutical company with defensive characteristics and modest growth:

Valuation Metrics: - P/E (forward 2031E): 18.5x - EV/EBITDA: 8.2x - Price-to-Sales: 1.18x - Dividend yield: 2.7% - Payout ratio: 62% of earnings

Comparison to Peers: - Roche: 24-26x P/E (premium for innovation leadership) - Novartis: 17-19x P/E (similar to Sanofi) - GSK: 15-17x P/E (generic exposure drag) - Merck: 21-23x P/E (premium for pipeline strength)

Sanofi's 18.5x multiple is middle-of-the-road; justified by: - Defensive vaccine and specialty care revenues - Modest but steady growth (3-4% organic) - High dividend yield (2.7%) - Lower execution risk vs. pure innovation stories

Valuation Scenarios (2030-2035 Outlook)

Base Case (70% probability):

Assumptions: - Revenue CAGR 2030-2035: 4-5% (specialty care +5%, vaccines +6%, generics -2%) - Operating margin: 25-26% (stable, mid-range of range) - EPS growth: 6-8% annually (organic growth + modest buybacks) - P/E multiple in 2035: 18-19x (stable, justified by dividend yield and growth)

2035 Fair Value: - 2035 EPS: EUR 8.20 (from EUR 5.92 in 2030, 6.7% CAGR) - Fair multiple: 18.5x - Fair value: EUR 151.70/share - CAGR from current: 5.6%

Bull Case (20% probability):

Assumptions: - Vaccine portfolio accelerates (RSV adoption exceeds EUR 5B peak; new vaccines approved) - AI drug discovery yields multiple successful programs - M&A brings in additional specialty care franchise - Revenue CAGR 2030-2035: 6-7% - Operating margin: 27-28% - EPS growth: 10-11% annually

2035 Fair Value: - 2035 EPS: EUR 10.00 - Fair multiple: 21-22x (premium for growth acceleration) - Fair value: EUR 210-220/share - CAGR from current: 31-33% total return (7-8% annualized)

Bear Case (10% probability):

Assumptions: - Vaccine portfolio disappoints (RSV adoption slower; competitive pressure) - AI drug discovery slower than expected - Patent cliffs hit specialty care franchise - Revenue CAGR 2030-2035: 1-2% - Operating margin: 22-23% - EPS growth: -1 to +1% annually

2035 Fair Value: - 2035 EPS: EUR 5.20 - Fair multiple: 16-17x (discount for slow growth) - Fair value: EUR 83-88/share - Return from current: -3 to -5% annualized

SECTION FOUR: INVESTMENT THESIS AND RISKS

Investment Thesis

Sanofi is attractive for dividend-focused and balanced portfolio allocators because it offers:

1. Defensive cash generation: Stable vaccines and specialty care generate predictable cash flows
2. Modest growth: 4-5% organic growth provides modest real return above inflation
3. Reasonable valuation: 18.5x P/E justified by dividend yield and quality
4. European exposure: Large-cap European pharma allocation for diversification
5. Dividend growth: Historical dividend growth 7-8% annually; sustainable at current payout ratio

Key Risks to Bull Case

1. Patent cliffs: Major specialty drugs (especially Dupilumab) face patent expiration 2031-2035; replacement products must launch on schedule
2. Vaccine competition: RSV vaccine faces competition from Pfizer, Moderna, others; pricing pressure likely
3. AI drug discovery underperformance: If AI integration slower than expected, pipeline acceleration delayed
4. M&A execution risk: Large acquisitions historically destroyed pharma shareholder value; Sanofi's track record is mixed
5. Regulatory pressure: EU/global pricing pressure on specialty drugs could compress margins

Suitable Investors

• Dividend growth investors seeking 6-8% annual total return
• European equity allocators (geographic exposure)
• Conservative pharmaceutical investors (lower execution risk vs. pure biotech)
• Balanced portfolio allocators (quality + dividend combination)

Unsuitable Investors

• High-growth seekers expecting >10% annual returns (growth insufficient)
• Value investors (not trading at significant discount)
• Biotech-focused investors (prefer higher-risk/higher-reward profiles)
• Non-EUR investors uncomfortable with currency risk

THE BULL CASE ALTERNATIVE: Vaccine Blockbuster Expansion and Specialty Care Acceleration

The bull case rests on three critical catalysts: (1) RSV vaccine and emerging vaccine portfolio achieve peak sales of EUR 9-11 billion annually by 2034-2035 (vs. EUR 7-8 billion base case), driven by higher-than-expected market penetration in aging populations, emerging market expansion, and successful commercial execution; (2) AI-accelerated drug discovery pipeline produces 3-4 successful new drug approvals by 2033-2035 in specialty care (rare diseases, oncology), expanding specialty care revenue to EUR 28-32 billion (vs. EUR 24-26 billion base case); (3) strategic M&A of vaccine-adjacent and specialty care assets (targeting biotech acquisitions or divested products from larger pharma) accelerates revenue growth and provides strategic optionality for portfolio consolidation.

Under bull case assumptions, Sanofi achieves revenue CAGR of 6-7% (2030-2035), operating margins expand to 27-28%, EPS grows 10-11% annually, and enterprise value reaches EUR 350-380 billion (vs. EUR 280-300 billion base case). Bull case entry points below EUR 50/share, with accumulation targets on recession weakness to EUR 43-46/share. Bull case probability: 25%.

THE DIVERGENCE: BEAR vs. BULL INVESTMENT OUTCOMES

Probability-Weighted Valuation (2035): - Bull case (25% probability) × €167.50 = €41.88 - Base case (55% probability) × €105 = €57.75 - Bear case (20% probability) × €72.50 = €14.50 - Probability-Weighted Fair Value (2035): €114.13 per share - Implied 5-year CAGR return: +15.7% annually

Current Market Assessment (June 2030): - Current price: €55/share - Implied 2035 fair value (PW): €114.13 - Implied return: +108% over 5 years, or +15.7% CAGR - Valuation: Moderately undervalued (52% discount to fair value)

Investment Implication: Sanofi at EUR 55 (June 2030) appears attractively undervalued relative to probability-weighted DCF analysis, offering 15.7% annual returns under probability-weighted scenarios and 5.8% under conservative base case. The bull case upside (173-236% total return) reflects aggressive but achievable vaccine portfolio expansion, successful AI-accelerated drug discovery, and strategic M&A execution. Bear case downside (+18-45%) is limited due to dividend income (2.7%+ yield) and defensive vaccine/specialty care positioning.

Sanofi is particularly attractive for: (1) dividend growth investors seeking mid-to-high single-digit returns with income, (2) European equity allocators seeking pharmaceutical exposure, (3) contrarian investors believing vaccine growth is underappreciated, (4) balanced portfolio investors seeking quality pharma at reasonable valuation. The stock is suitable for 5-10 year holding periods with rebalancing on achievement of upside scenarios.

Rating upgrade to BUY with higher conviction; target EUR 100-120 (2033) and EUR 140-180 (2035).

SECTION FIVE: INVESTMENT RECOMMENDATION

Rating: BUY

Target Price (2032-2033 horizon): EUR 72/share

Rationale: - Current price of EUR 55 represents modest discount to fair value range (EUR 60-75) - Target implies 30% upside over 3-year horizon (9-10% annualized) - Dividend yield of 2.7% provides income component - Total return target of 11-12% annually (capital appreciation + dividend) is reasonable for pharmaceutical quality

Investment Thesis Confidence: MODERATE-HIGH - Execution risk on patent cliff management and vaccine competition are material - BUT: Defensive nature and dividend income provide downside protection - Expected volatility: Moderate (pharma sector volatility, typically 15-20% annual)

Suitable Holding Period: 5+ years - Medium-term rebalancing risk if patent cliffs hit earlier than expected - Long-term structural growth in specialty care and vaccines provides multi-year visibility

CONCLUSION

Sanofi represents quality European pharmaceutical company successfully executing strategic transition from commodity generics toward specialty care and vaccine focus. By June 2030, the company has demonstrated successful execution and achieved sustainable business model positioned for modest organic growth combined with high dividend yield.

At EUR 55/share with 18.5x P/E and 2.7% dividend yield, Sanofi offers reasonable risk-adjusted return potential for balanced investors seeking pharmaceutical exposure with lower execution risk profile. The bull case provides potential for 7-8% annualized returns; base case of 5-6% remains attractive relative to broader market alternatives.

Recommended for dividend-focused and balanced portfolio allocators; avoid for high-growth seekers.

Word Count: 2,956

REFERENCES & DATA SOURCES

1. Bloomberg (Q2 2030): "Sanofi Q2 2030 Earnings: Biotech Integration and AI Drug Development"
2. McKinsey & Company (2030): "AI-Driven Drug Discovery: Clinical Trial and Development Acceleration"
3. Reuters (2029): "Pharmaceutical Company Strategic M&A and Biotech Integration"
4. Morgan Stanley Healthcare Equity Research (June 2030): "Diversified Pharma Valuations"
5. Gartner (2029): "Healthcare AI and Precision Medicine Platforms"
6. Goldman Sachs (2030): "Pharmaceutical Sector Innovation and Competitive Positioning"
7. S&P Global (2030): "Pharmaceutical Industry Profitability and Technology ROI"
8. Deloitte (2030): "Pharmaceutical Digital Transformation"
9. Boston Consulting Group (2030): "Biopharma R&D Efficiency and Innovation"
10. Tufts Center for Drug Development (2030): "Pharmaceutical Development Productivity Trends"
11. Nature Medicine (2030): "AI Applications in Clinical Development"
12. EvaluatePharma (2030): "Drug Development Timeline and Success Rates"